MindWalk Holdings Corp. (HYFT)
NASDAQ: HYFT · Real-Time Price · USD
1.867
+0.017 (0.94%)
Sep 9, 2025, 12:59 PM - Market open
MindWalk Holdings Employees
As of April 30, 2025, MindWalk Holdings had 102 total employees, including 81 full-time and 21 part-time employees. The number of employees increased by 1 or 0.99% compared to the previous year.
Employees
102
Change (1Y)
1
Growth (1Y)
0.99%
Revenue / Employee
$173,968
Profits / Employee
-$214,508
Market Cap
86.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 102 | 1 | 0.99% |
| Apr 30, 2024 | 101 | -1 | -0.98% |
| Apr 30, 2023 | 102 | 17 | 20.00% |
| Apr 30, 2022 | 85 | 12 | 16.44% |
| Apr 30, 2021 | 73 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
HYFT News
- 6 days ago - ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT” - Business Wire
- 7 days ago - ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York - Business Wire
- 13 days ago - ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation - Business Wire
- 4 weeks ago - AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd. - Business Wire
- 4 weeks ago - ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation - Business Wire
- 6 weeks ago - ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript - Seeking Alpha
- 6 weeks ago - ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA - Business Wire
- 6 weeks ago - ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic - Business Wire